Monday, December 05, 2016
 
 
Video: Page (1) of 1 - 04/27/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Repligen Tumbles 45% On Pancreatic Cancer Drug Data Request (RGEN)

By DMO Affiliate
4-26-12-Shares of Repligen (NASDAQ:RGEN) are trading over 45% lower after trading resumed in the shares that were halted on news that biotechnology firm would be asked for more information on its pancreatic imaging treatment by the FDA.The FDA, which was
Repligen Tumbles 45% On Pancreatic Cancer Drug Data Request (RGEN)




Page: 1


null
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines